Klein Ariane, Reinhard Harald, Mueller Annette M, Horneff Gerd
Department of General Pediatrics, Asklepios Clinic Sankt Augustin, Sankt Augustin, Germany.
Center of Pediatric Pathology, MVZ Venusberg, University Clinic Bonn, Bonn, Germany.
Eur J Rheumatol. 2017 Jun;4(2):136-138. doi: 10.5152/eurjrheum.2016.032. Epub 2017 Feb 23.
A case of a 16-year-old female with polyarticular juvenile idiopathic arthritis (JIA) since the age of 4 years is reported here. This patient also suffered from multiple congenital anomalies. On long-term treatment with oral methotrexate (MTX) and etanercept, multiple subcutaneous nodules were detected, which were accompanied by increased lactate dehydrogenase and uric acid levels. A biopsy of the largest nodule revealed Epstein-Barr (EB) virus-positive diffuse large B-cell lymphoma (DLBCL). The patient was classified as clinical stage IIIA due to a mediastinal lesion. Immunosuppressive treatment was discontinued immediately, which led to regression of the remaining nodules and normalization of the lactate dehydrogenase levels. The patient was considered to have an iatrogenic lymphoproliferative disorder classified as "other iatrogenic immunodeficiency-associated lymphoproliferative disorders" by the World health organization (WHO). To our knowledge, this is the first case report of a JIA patient with EBV-positive DLBCL following the administration of etanercept and methotrexate and spontaneous regression of lymphoproliferation after the discontinuation of antirheumatic treatment.
本文报告了一例16岁女性患者,自4岁起患有多关节型幼年特发性关节炎(JIA)。该患者还患有多种先天性异常。在长期口服甲氨蝶呤(MTX)和依那西普治疗期间,发现多个皮下结节,同时乳酸脱氢酶和尿酸水平升高。对最大的结节进行活检显示,爱泼斯坦-巴尔(EB)病毒阳性弥漫性大B细胞淋巴瘤(DLBCL)。由于纵隔病变,该患者被分类为临床III A期。立即停止免疫抑制治疗,这导致其余结节消退,乳酸脱氢酶水平恢复正常。该患者被认为患有医源性淋巴增殖性疾病,世界卫生组织(WHO)将其归类为“其他医源性免疫缺陷相关淋巴增殖性疾病”。据我们所知,这是首例关于JIA患者在使用依那西普和甲氨蝶呤后发生EBV阳性DLBCL且在停用抗风湿治疗后淋巴增殖自发消退的病例报告。